These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 3948308)

  • 21. Modification of alkylating agent cytotoxicity by cisplatin.
    Horsman MR; Hirst DG; Brown DM; Brown JM
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1669-73. PubMed ID: 6541216
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Antineoplastic spectrum of mitoxantrone in rat ascitic hepatoma].
    Satoh H
    Gan To Kagaku Ryoho; 1982 Jan; 9(1):26-30. PubMed ID: 7184361
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lack of effect of cisplatin on i.v. L-PAM plasma pharmacokinetics in ovarian cancer patients.
    Zucchetti M; D'Incalci M; Willems Y; Cavalli F; Sessa C
    Cancer Chemother Pharmacol; 1988; 22(1):87-9. PubMed ID: 3396150
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Myocardial effects of mitoxantrone and doxorubicin in the mouse and guinea pig.
    Perkins WE; Schroeder RL; Carrano RA; Imondi AR
    Cancer Treat Rep; 1984 Jun; 68(6):841-7. PubMed ID: 6733698
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. I. Enhancement of in vivo rejection responses by combined chemotherapy-immunotherapy.
    Adler A; Altbaum I
    J Natl Cancer Inst; 1982 Jun; 68(6):963-9. PubMed ID: 6953275
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevention of carcinogenicity of anticancer drugs by metallothionein induction.
    Satoh M; Kondo Y; Mita M; Nakagawa I; Naganuma A; Imura N
    Cancer Res; 1993 Oct; 53(20):4767-8. PubMed ID: 8402657
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety assessment of a new anticancer compound, mitoxantrone, in beagle dogs: comparison with doxorubicin. I. Clinical observations.
    Henderson BM; Dougherty WJ; James VC; Tilley LP; Noble JF
    Cancer Treat Rep; 1982 May; 66(5):1139-43. PubMed ID: 7083216
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Theophylline reversal of alkylator-induced replicon initiation inhibition: no correlation with DDP-induced cytotoxicity.
    Ducore JM; Rosenstein BS
    Mutat Res; 1984 Oct; 141(2):117-21. PubMed ID: 6541756
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose cyclophosphamide or melphalan with escalating doses of mitoxantrone and autologous bone marrow transplantation for refractory solid tumors.
    Mulder PO; Sleijfer DT; Willemse PH; de Vries EG; Uges DR; Mulder NH
    Cancer Res; 1989 Aug; 49(16):4654-8. PubMed ID: 2545349
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytotoxic interactions of tumor necrosis factor, melphalan and 41.8 degrees C hyperthermia.
    Robins HI; d'Oleire F; Kutz M; Bird A; Schmitt-Tiggelaar CL; Cohen JD; Spriggs DR
    Cancer Lett; 1995 Feb; 89(1):55-62. PubMed ID: 7882302
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of scheduling on two-drug combinations of alkylating agents in vivo.
    Teicher BA; Holden SA; Jones SM; Eder JP; Herman TS
    Cancer Chemother Pharmacol; 1989; 25(3):161-6. PubMed ID: 2513139
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Importance of Lyt 2+ T-cells in the curative effectiveness of a low dose of melphalan for mice bearing a large MOPC-315 tumor.
    Mokyr MB; Barker E; Weiskirch LM; Takesue BY; Pyle JM
    Cancer Res; 1989 Aug; 49(16):4597-606. PubMed ID: 2568174
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NLCQ-1, a novel hypoxic cytotoxin: potentiation of melphalan, cisDDP and cyclophosphamide in vivo.
    Papadopoulou MV; Ji M; Bloomer WD
    Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):775-9. PubMed ID: 9845094
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interleukin 2 requirement for the in vitro generation of antitumor cytotoxicity by thymocytes from melphalan-cured MOPC-315 tumor bearers.
    Mokyr MB; Bartik MM; Ahn MC
    Cancer Res; 1989 Feb; 49(4):870-6. PubMed ID: 2783557
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Melphalan and other anticancer modalities up-regulate B7-1 gene expression in tumor cells.
    Sojka DK; Donepudi M; Bluestone JA; Mokyr MB
    J Immunol; 2000 Jun; 164(12):6230-6. PubMed ID: 10843675
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Experimental modification of the nephro- and gastroenterotoxicity of cisplatin].
    Kulik GI; Chekhun VF; Pel'kis FP; Boĭm TM
    Vopr Onkol; 1988; 34(12):1477-81. PubMed ID: 3218150
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation between experimentally and clinically demonstrated activity of two new cytotoxic agents in breast cancer.
    Bailey MJ; Smith IE
    Anticancer Res; 1985; 5(4):419-22. PubMed ID: 3839994
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Some approaches to improve the therapeutic effectiveness of adoptive chemoimmunotherapy with spleen cells from melphalan-treated BALB/c mice bearing a large MOPC-315 tumor.
    Weiskirch LM; Mokyr MB
    Int J Cancer; 1992 Apr; 51(1):84-92. PubMed ID: 1563847
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative molecular pharmacology in leukemic L1210 cells of the anthracene anticancer drugs mitoxantrone and bisantrene.
    Bowden GT; Roberts R; Alberts DS; Peng YM; Garcia D
    Cancer Res; 1985 Oct; 45(10):4915-20. PubMed ID: 4027978
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of purine nucleoside analogs on the response of the RIF-1 tumor to melphalan in vivo.
    Horsman MR; Brown DM; Hirst DG; Brown JM
    Int J Radiat Oncol Biol Phys; 1986 May; 12(5):801-6. PubMed ID: 3486861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.